PriceTargets.com logo

Harpoon Therapeutics - HARP Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $27.25
  • Forecasted Upside: 18.43%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$23.01 As of 03/11/2024 01:00 AM ET
+0 (0.00%)
Get New Harpoon Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HARP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HARP

Analyst Price Target is $27.25
▲ +18.43% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Harpoon Therapeutics in the last 3 months. The average price target is $27.25, with a high forecast of $40.00 and a low forecast of $23.00. The average price target represents a 18.43% upside from the last price of $23.01.

This chart shows the closing price for HARP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 6 polled investment analysts is to hold stock in Harpoon Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/26/2024OppenheimerReiterated RatingOutperform ➝ OutperformN/A
2/26/2024CitigroupReiterated RatingBuy ➝ Neutral$13.00 ➝ $23.00Low
1/16/2024TD CowenReiterated RatingOutperform ➝ Market PerformLow
1/8/2024Leerink PartnrsDowngradeOutperform ➝ Market PerformLow
1/8/2024HC WainwrightDowngradeBuy ➝ Neutral$12.00 ➝ $23.00Low
1/5/2024OppenheimerInitiated CoverageOutperform$23.00Low
12/13/2023HC WainwrightBoost TargetBuy ➝ Buy$7.50 ➝ $12.00Low
11/20/2023TD CowenInitiated CoverageOutperformLow
10/24/2023CitigroupLower TargetBuy ➝ Buy$33.00 ➝ $13.00Low
9/18/2023CitigroupLower TargetBuy ➝ Buy$60.00 ➝ $33.00Low
9/14/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$80.00 ➝ $40.00Low
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$45.00Low
5/15/2023500.comReiterated RatingReiteratesLow
4/3/2023Canaccord Genuity GroupLower TargetBuy$160.00 ➝ $80.00Low
3/29/2023HC WainwrightLower TargetBuy$70.00 ➝ $45.00Low
12/14/2022Truist FinancialDowngradeBuy ➝ Hold$20.00Low
11/17/2022Robert W. BairdLower Target$15.00Low
11/15/2022Robert W. BairdDowngradeOutperform ➝ NeutralLow
11/15/2022SVB LeerinkLower TargetOutperform$100.00 ➝ $40.00Low
8/29/2022CitigroupLower TargetBuy$70.00 ➝ $60.00Low
8/23/2022Truist FinancialLower TargetBuy$120.00 ➝ $70.00Low
8/15/2022HC WainwrightLower TargetBuy$180.00 ➝ $70.00Low
8/11/2022SVB LeerinkLower TargetOutperform$130.00 ➝ $100.00Low
8/11/2022Robert W. BairdLower Target$140.00 ➝ $80.00Low
8/11/2022Piper SandlerLower TargetOverweight$90.00 ➝ $70.00Low
7/6/2022Canaccord Genuity GroupReiterated RatingBuy$160.00N/A
5/27/2022Piper SandlerLower Target$140.00 ➝ $90.00Low
5/17/2022Roth CapitalBoost Target$140.00 ➝ $180.00High
5/16/2022WedbushBoost TargetNeutral ➝ Outperform$50.00 ➝ $70.00High
5/13/2022Piper SandlerLower Target$150.00 ➝ $140.00Medium
5/9/2022Cantor FitzgeraldReiterated RatingOverweightMedium
3/23/2022Canaccord Genuity GroupLower Target$300.00 ➝ $140.00Low
3/16/2022CitigroupLower TargetBuy$140.00 ➝ $70.00High
3/14/2022Roth CapitalLower Target$310.00 ➝ $140.00Low
3/14/2022Robert W. BairdLower Target$350.00 ➝ $140.00High
3/14/2022HC WainwrightLower TargetBuy$310.00 ➝ $180.00High
3/14/2022Piper SandlerLower TargetOverweight$270.00 ➝ $150.00High
3/11/2022SVB LeerinkLower Target$190.00 ➝ $130.00High
12/16/2021SVB LeerinkReiterated RatingBuyHigh
11/17/2021CitigroupLower TargetBuy$160.00 ➝ $140.00Medium
11/11/2021SVB LeerinkLower TargetOutperform$250.00 ➝ $190.00High
10/18/2021Cantor FitzgeraldReiterated RatingOverweightLow
9/27/2021CitigroupUpgradeNeutral ➝ Buy$160.00High
8/15/2021Robert W. BairdReiterated RatingBuy$350.00Medium
8/6/2021Piper SandlerReiterated RatingOverweight$350.00 ➝ $300.00Low
8/6/2021SVB LeerinkLower TargetOutperform$290.00 ➝ $250.00High
6/8/2021CitigroupDowngradeBuy ➝ NeutralMedium
6/7/2021HC WainwrightReiterated RatingBuy$310.00High
6/7/2021WedbushDowngradeOutperform ➝ NeutralHigh
5/28/2021Cantor FitzgeraldInitiated CoverageOverweight$400.00Medium
5/10/2021Piper SandlerInitiated CoverageOverweight$350.00Medium
5/9/2021SVB LeerinkReiterated RatingBuy$290.00Medium
3/22/2021Robert W. BairdReiterated RatingBuy$350.00High
3/17/2021SVB LeerinkLower TargetOutperform$310.00 ➝ $290.00High
3/11/2021SVB LeerinkLower TargetOutperform$310.00 ➝ $290.00Medium
1/4/2021SVB LeerinkBoost TargetOutperform$280.00 ➝ $310.00N/A
12/23/2020HC WainwrightReiterated RatingBuy$310.00 ➝ $310.00N/A
8/10/2020CitigroupBoost TargetBuy$240.00 ➝ $250.00Medium
8/6/2020WedbushBoost TargetOutperform$360.00 ➝ $380.00Low
6/30/2020CitigroupBoost TargetBuy$230.00 ➝ $240.00Medium
6/1/2020WedbushBoost TargetOutperform$260.00 ➝ $360.00High
6/1/2020HC WainwrightReiterated RatingBuyHigh
5/29/2020Roth CapitalBoost TargetBuy$250.00 ➝ $310.00High
5/22/2020Piper SandlerInitiated CoverageOverweight$350.00High
5/14/2020HC WainwrightReiterated RatingBuy$280.00Medium
3/13/2020HC WainwrightReiterated RatingBuy$280.00High
2/27/2020SunTrust BanksInitiated CoverageBuy$310.00High
2/3/2020HC WainwrightInitiated CoverageBuy$280.00High
11/13/2019Roth CapitalInitiated CoverageBuy$250.00 ➝ $250.00High
5/24/2019CitigroupReiterated RatingBuy ➝ Buy$230.00High
(Data available from 4/25/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
9/28/2023
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
Mentions as of
10/28/2023
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/27/2023
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 6 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/26/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 6 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Harpoon Therapeutics logo
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
Read More

Today's Range

Now: $23.01
Low: $23.01
High: $23.01

50 Day Range

MA: $22.89
Low: $22.34
High: $23.01

52 Week Range

Now: $23.01
Low: $3.11
High: $23.21

Volume

N/A

Average Volume

1,516,200 shs

Market Capitalization

$389.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.11

Frequently Asked Questions

What sell-side analysts currently cover shares of Harpoon Therapeutics?

The following Wall Street sell-side analysts have issued reports on Harpoon Therapeutics in the last year: 500.com Limited, Canaccord Genuity Group Inc., Citigroup Inc., HC Wainwright, Leerink Partnrs, Oppenheimer Holdings Inc., and TD Cowen.
View the latest analyst ratings for HARP.

What is the current price target for Harpoon Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Harpoon Therapeutics in the last year. Their average twelve-month price target is $27.25, suggesting a possible upside of 18.4%. Canaccord Genuity Group Inc. has the highest price target set, predicting HARP will reach $40.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $23.00 for Harpoon Therapeutics in the next year.
View the latest price targets for HARP.

What is the current consensus analyst rating for Harpoon Therapeutics?

Harpoon Therapeutics currently has 4 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in HARP, but not buy more shares or sell existing shares.
View the latest ratings for HARP.

What other companies compete with Harpoon Therapeutics?

Other companies that are similar to Harpoon Therapeutics include Nektar Therapeutics, NGM Biopharmaceuticals, Kinnate Biopharma, Mersana Therapeutics and Heron Therapeutics. Learn More about companies similar to Harpoon Therapeutics.

How do I contact Harpoon Therapeutics' investor relations team?

Harpoon Therapeutics' physical mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (650) 443-7400 and its investor relations email address is [email protected]. The official website for Harpoon Therapeutics is www.harpoontx.com. Learn More about contacing Harpoon Therapeutics investor relations.